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Abstract
Background: Bivalirudin has been shown to be safe and effective during percutaneous
coronary interventions (PCI) of native coronary arteries in the REPLACE 2 trial. The safety of
bivalirudin during PCIs in heart transplant patients is not known.
Methods: Heart transplant patients who had undergone PCI of de novo lesions and received
bivalirudin during the procedure were included in the study. Medical records were reviewed for
the occurrence of death, myocardial infarction, target vessel revascularization or major bleeding
up to 30 days after discharge. The results were compared with the REPLACE 2 trial and with
a control group of heart transplant recipients who received heparin during their procedures.
Results: There were 51 separate PCIs performed in 30 patients in the study group. The mean
age was 56 ± 12 years and 6 (20%) were women. The control group consisted of 24 patients
who had undergone 35 PCIs. There were no deaths, myocardial infarctions or target vessel
revascularization during the follow-up period in the study group. The combined endpoint of
death, myocardial infarctions, target vessel revascularization and major bleeding requiring
two or more units of packed red blood cells occurred in 2 (3.9%) patients compared to
275 (9.2%) patients in the REPLACE 2 trial (p = 0.195) and 5 (14.3%) in the control group (p = 0.115).
Conclusion: Bivalirudin is a safe antithrombotic medication to use during elective PCI in
heart transplant patients with cardiac allograft vasculopathy. (Cardiol J 2007; 14: 458–462)
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Introduction
Cardiac allograft vasculopathy (CAV) occurs in
42% of heart transplant patients three years after
transplantation and is the leading cause of death in
these patients within one and three years [1].
Although CAV is pathologically distinct from native
coronary artery disease [2], percutaneous coronary
intervention (PCI) is effective and safe in this pa-
tient population [3–7]. Heparin is the traditional
antithrombotic agent used during PCI in heart
transplant recipients. Interest in the use of bivaliru-
din in this population has increased in the light of
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studies that have shown its safety and effectiveness
during PCI of native coronary artery disease [8–11].
We report on the safety of bivalirudin use in one
center during PCI in heart transplant patients and
compare the results with historical controls from
the Randomized Evaluation in PCI Linking Angio-
max to reduced Clinical Events (REPLACE) 2 trial
that was performed in non-transplant patients and
to heart transplant patients from our center who
received heparin during their PCI.
Methods
Patient population
The records of heart transplant recipients who
had undergone a PCI at the University of Alabama
at Birmingham from June 2003 to December 2005
were retrospectively reviewed. Patients who had
a PCI of one or more de novo lesions and who re-
ceived bivalirudin during the index procedure were
included in the study. Patients who underwent PCI
solely for in-stent restenotic lesions were excluded.
A control group of heart transplant patients who un-
derwent PCI from January 2002 till January 2007
and received heparin during the procedure was
identified.
Study protocol
Bivalirudin was administered as a bolus of
0.75 mg/kg prior to the start of the intervention, fol-
lowed by an infusion of 1.75 mg/kg/h for the dura-
tion of the intervention. Glycoprotein 2b3a inhibi-
tors were used at the operator’s discretion. Patients
who underwent PCI of multiple vessels or lesions
during the same visit to the catheterization labora-
tory were considered to have a single procedure,
and each visit to the catheterization laboratory was
considered a separate procedure.
Outcomes
As in the REPLACE 2 trial, the primary end-
point consisted of a composite of death, myocardial
infarction, target vessel revascularization or major
bleeding within 30 days of the intervention. The
secondary endpoint consisted of a composite of
death, myocardial infarction or target vessel revas-
cularization. Single endpoints from the above list-
ed composite endpoints were also compared.
Major bleeding was defined as intracranial, in-
traocular or retroperitoneal hemorrhage, clinically
overt blood loss resulting in a decrease in hemo-
globin of more than 3 mg/dl, any decrease in hemo-
globin of more than 4 mg/dl or transfusion of two or
more units of packed red blood cells or whole blood.
Cardiac markers were collected every 8 hours and
for at least three sets after each procedure. Myo-
cardial infarction was defined as new significant
Q waves in two or more contiguous leads or elevation
of CPK or CK-MB ≥ 3 times the upper limit of the
norm within two days of revascularization and
≥ 2 times the upper limits of the norm outside the
setting of revascularization. Therefore both the
bleeding and the clinical endpoints were identical
to REPLACE 2.
Statistical analysis
Statistical analysis was performed using the
SPSS software (Version 11.5, SPSS Inc., Chicago,
Illinois). The results are expressed as a percentage
frequency or mean ± 1 standard deviation (SD)
where appropriate. Categorical variables were com-
pared using a c2 test. A two-tailed p-value < 0.05
was considered statistically significant.
Results
The study group consisted of 30 heart trans-
plant recipients who underwent 51 coronary pro-
cedures using bivalirudin as an antithrombotic
agent. The control group included 24 patients who
underwent 35 PCIs. The patients’ baseline charac-
teristics at the time of the procedure are shown in
Table 1. The two groups are comparable, with the
exception that patients who received heparin dur-
ing their procedures had a higher likelihood of hav-
ing a history of CAV or having undergone a PCI.
The results of coronary angiography and the pro-
cedural characteristics are shown in Table 2. In the
study group stents were deployed in 48 (94%) pro-
cedures. The remaining 3 (6%) procedures consist-
ed of pressure wire or intravascular ultrasound eval-
uations of intermediate coronary lesions with no
intervention performed. We elected not to exclude
these patients, although they did not undergo an
intervention since they had received bivalirudin and
were at risk of complications. All except 1 patient
(98%) received clopidogrel before, during or after
the procedure. The patient who did not receive
clopidogrel had pressure wire evaluation of a lesion
and did not require PCI.
The mean hospitalization duration was 2.7 ±
± 2.0 days (range 2–13) for the study group com-
pared to 2.9 ± 1.9 days (range 1–10) in the control
group, both groups having a median of two days. In
the patients who received bivalirudin there were
two episodes of major bleeding, one of which oc-
curred during the index hospitalization and involved
right femoral artery blood loss that required 5 units
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of packed RBC transfusion. The second episode oc-
curred 30 days after the index procedure, when the
patient presented with maroon stools and fatigue.
She was hospitalized and was transfused with
4 units of packed red blood cells and 2 units of plate-
lets. Upper gastrointestinal endoscopy revealed two
duodenal ulcers with a visible vessel and an over-
lying clot in one of the ulcers. The patient was on
aspirin and clopidogrel, which were suspected as
the culprits of her upper gastrointestinal bleed.
Both were stopped and the bleeding was control-
led with no further interventions. There were no
deaths, myocardial infarctions or urgent target ves-
sel revascularizations. The composite endpoint of
death, myocardial infarction, urgent target vessel
revascularization or major bleeding occurred in
2 (3.9%) procedures in the first 30 days. The sum-
mary of events and the comparisons with the
REPLACE 2 results and with the control group are
presented in Table 3. Glycoprotein 2b3a inhibitors
were provisionally used in 4 (8%) procedures in ad-
dition to bivalirudin (3 patients received Reopro and
1 patient eptifibatide) at the operator’s discretion,
but none had any complication and the hospital stay
was two days for all 4 patients. In the control group,
glycoprotein 2b3a inhibitors were used in 16 (46%)
procedures. The two myocardial infarctions as well
as the three major bleeding episodes in the control
group occurred in the patients who received glyco-
protein 2b3a inhibitors on top of heparin.
Discussion
In this observational study we examined the
safety of bivalirudin as the anticoagulant during
elective coronary procedures for coronary vascu-
Table 1. Baseline characteristics.
Characteristics Bivalirudin (n = 30) Heparin (n = 24) p
Age (years) 56 ± 12 58 ± 13 NS
Women 6 (20%) 6 (25%) NS
Race
Caucasian 20 (67%) 17 (71%) NS
African American 9 (30%) 7 (29%)
Other 1 (3%) 0 (0%)
Reason for heart transplant
Ischemic cardiomyopathy 17 (57%) 12 (50%) NS
Non-ischemic cardiomyopathy 8 (27%) 9 (38%)
Congenital heart disease 2 (7%) 0 (0%)
Other 3 (10%) 3 (12%)
Diabetes mellitus 16 (53%) 13 (54%) NS
Hypertension 25 (83%) 22 (92%) NS
Peripheral vascular disease 2 (7%) 4 (17%) NS
Prior stroke 3 (10%) 3 12%) NS
Chronic kidney disease 15 (50%) 15 (63%) NS
History of coronary vasculopathy 24 (80%) 24 (100%) 0.028
Prior coronary intervention 15 (50%) 20 (83%) 0.004
Medications*
Aspirin 48 (96%) 33 (94%) NS
Clopidogrel — on admission 38 (75%) 31 (89%) NS
Clopidogrel — on discharge 50 (98%) 33 (94%) NS
Warfarin 4 (8%) 0 (0%) NS
Statin 37 (73%) 29 (83%) NS
Beta-blocker 7 (14%) 6 (17%) NS
Calcium channel blocker 46 (90%) 27 (77%) NS
Nitrates 1 (2%) 5 (14%) 0.039
Oral rapamycin 18 (35%) 8 (23%) NS
*Medications relate to time of procedure and are relative to the number of procedures rather than to the number of patients
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lopathy in heart transplant recipients. Since there
are no data in the literature about the safety of the
traditional anticoagulant, heparin, we compared our
data for this population with the bivalirudin arm of
the REPLACE 2 trial, which showed that bivaliru-
din with provisional glycoprotein 2b3a inhibition
was not inferior to heparin with planned glycopro-
tein 2b3a inhibition in relation to ischemic events
and was associated with statistically fewer bleed-
ing events [8]. We also compared our results with
a control group of heart transplant recipients who
underwent PCI using heparin at our center. Our
findings, which were tailored to mirror the events
monitored in REPLACE 2, showed significantly
lower rates of ischemic events (0% for the compos-
ite of death, myocardial infarction and target ves-
sel revascularization) and a non-significant trend to
a lower rate for the composite endpoint of ischem-
ic events and bleeding at 30 days in comparison with
patients with native coronary arteries undergoing
a PCI (Table 3). Neither outcome was statistically
different from the control group. Unlike REPLACE 2,
only a small minority of patients received bare metal
stents (Table 2).
We believe that these findings are of practical
value to the cardiologist caring for heart transplant
patients with CAV. The pathophysiology of CAV is
different from that of native coronary artery disease,
making it impossible to extrapolate that bivalirudin
is safe to use in this patient population without this
data being available. Previous reports have estab-
lished the benefit of PCI in CAV, with procedural
Table 2. Procedural characteristics.
Characteristics Bivalirudin (n = 51) Heparin (n = 35)
Vasculopathy > 50% of lumen*
Left main** 1 (2%) 2 (6%)
Left anterior descending** 35 (69%) 26 (74%)
Left circumflex** 23 (45%) 25 (71%)
Right coronary artery** 18 (35%) 16 (46%)
Target vessel (not mutually exclusive)
Left main** 1 (2%) 2 (6%)
Left anterior descending** 28 (55%) 19 (54%)
Left circumflex** 13 (25%) 13 (37%)
Right coronary artery** 10 (20%) 5 (14%)
Procedure type
Balloon angioplasty alone 0 (0%) 0 (0%)
Drug-eluting stent*** 47 (92%) 25 (71%)
Heparin coated stent*** 0 (0%) 9 (26%)
Bare metal stent*** 1 (2%) 1 (3%)
Pressure wire or intravascular ultrasound 3 (6%) 0 (0%)
*Lesion severity as determined by cardiologist reading the angiogram for clinical purposes; **stated artery or any of its major branches; ***either
primary stenting alone or included pre- or post-dilatation with balloon angioplasty
Table 3. Events during the first 30 days and comparison with the REPLACE 2.
Events Bivalirudin Heparin p* REPLACE 2 p*
(n = 51)  (n = 35)  (n = 2994)
Death 0 (0%) 0 (0%) Not applicable 7 (0.2%) 0.729
Myocardial infarction 0 (0%) 2 (5.7%) 0.163 207 (7%) 0.052
Target vessel revascularization 0 (0%) 0 (0%) Not applicable 35 (1.2%) 0.437
Major bleeding 2 (3.9%) 3 (8.6%) 0.393 71 (2.4%) 0.473
Any transfusion 2 (3.9%) 1 (2.9%) 1.000 50 (1.7%) 0.218
Transfusion of ≥ 2 U of PC RBC 2 (3.9%) 1 (2.9%) 1.000 39 (1.3%) 0.108
Death + MI + TVR + major bleeding 2 (3.9%) 5 (14.3%) 0.115 275 (9.2%) 0.195
Death + MI + TVR 0 (0%) 2 (5.7%) 0.163 227 (7.6%) 0.041
*Compared to the bivalirudin group; PC RBC — packed cell red blood cells; MI — myocardial infarction; TVR — target vessel revascularization
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success rates higher than 90% and at acceptable
restenosis rates, especially with the use of drug-
eluting stents [12–14]. Most of these studies includ-
ed a small number of patients and did not address
the 30-day outcomes of these patients but rather
the long-term clinical and angiographic outcomes,
making a direct comparison between different an-
tithrombotic agents in this population difficult.
Study limitations
We are aware of the limitations on the conclu-
sions of our single-center retrospective study of
a small group of patients. It is important to realize
that in order to include this number of patients we
surveyed all the heart transplant patients at our
center that had had PCI over several years. It is also
of note that we did not perform routine angiogra-
phy at one month and that the lack of ischemic
events could be secondary to the fact that transplant
recipients have denervated hearts and rarely
present with chest pain [15]. We did, however,
check routine cardiac markers, including troponins,
after PCI on all patients.
Conclusion
Bivalirudin is a safe antithrombotic medication
to use during elective PCI in heart transplant pa-
tients with CAV. Future multicenter randomized
studies are needed to compare the efficacy of
heparin with that of bivalirudin in this unique sub-
set of patients undergoing PCI.
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